146923-55-9

Upstream product

• 161282-51-5 tert-butyl (S)-2-<(benzyloxy)carbonylamino>-3-(thiophen-2-yl)propanoate 
• 98-03-3 thiophene-2-carbaldehyde 
• 161282-35-5 tert-butyl (Z)-2-<(benzyloxy)carbonylamino>-3-(thiophen-2-yl)prop-2-enoate 
• 501-53-1 benzyl chloroformate 
• 22951-96-8 L-3-(2-thienyl)alanine 
• 75-09-2 dichloromethane 
• 584-08-7 potassium carbonate 
• 118553-53-0 rac-tert-butyl 2-<(benzyloxy)carbonylamino>-2-(dimethoxyphosphoryl)-acetate 
• 89525-07-5 (+/-)-2-<(benzyloxycarbonyl)amino>-2-(dimethoxyphosphinyl)acetic acid 
• 100945-15-1 N-(benzyloxycarbonyl)phosphonoglycine trimethyl ester 
• 634920-02-8 4-thiophen-2-ylmethyl-oxazolidine-2,5-dione 
• 2021-58-1 rac-3-(2-thienyl)alanine 
• 394210-39-0 2,5-dioxo-4-thiophen-2-ylmethyl-oxazolidine-3-carboxylic acid benzyl ester 

Relevant academic research and scientific papers

PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF

This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.

Method of making HIV protease inhibitors

A method of making HIV protease inhibitors of general formula (1): These HIV compounds inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optically other antiviral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

HIV protease inhibitors

HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

HIV protease inhibitors

HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

Synthesis of enantiomerically pure D- and L-(heteroaryl)alanines by asymmetric hydrogenation of (Z)-α-amino-α,β-didehydro esters

Homogeneous asymmetric hydrogenation of a wide range of methyl and tert-butyl (Z)-2-(acylamino)-3-(heteroaryl)acrylates (see 1a-f and 2a-d, f, g, resp.) catalyzed by diphosphinerhodium catalysts was studied for the synthesis of enantiomerically pure 3-fur